Tessa Romero
Stock Analyst at JP Morgan
(3.93)
# 547
Out of 4,784 analysts
58
Total ratings
44.19%
Success rate
13.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $11.45 | +48.47% | 5 | Mar 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $72 → $68 | $27.65 | +145.93% | 6 | Mar 5, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $6.87 | +453.13% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $1.03 | +1,356.31% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $0.72 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $32.84 | -5.60% | 5 | Oct 14, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $43.19 | +64.39% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $5.83 | +397.43% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $23.27 | +33.22% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $30.28 | +51.92% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $17.07 | +46.46% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $4.10 | +387.80% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $4.81 | +45.53% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $34.26 | +60.54% | 2 | Apr 25, 2023 |
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $11.45
Upside: +48.47%
Biohaven
Mar 5, 2025
Maintains: Overweight
Price Target: $72 → $68
Current: $27.65
Upside: +145.93%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $6.87
Upside: +453.13%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $1.03
Upside: +1,356.31%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.72
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $32.84
Upside: -5.60%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $43.19
Upside: +64.39%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $5.83
Upside: +397.43%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $23.27
Upside: +33.22%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $30.28
Upside: +51.92%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $17.07
Upside: +46.46%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $4.10
Upside: +387.80%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $4.81
Upside: +45.53%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $34.26
Upside: +60.54%